drug delivery system
cell chamber
cell therapies
drug peaks
cell confinement
controlled drug release
standard intravenous IFN-ß delivery
subcutaneous delivery
new interferon-ß
optical performance
cellular response
membrane acts
porous membrane
new bio-electronic cell
production of IFN
Optoelectronics miniaturization
long-term safety
market demands
adverse effects of current cellular therapies
high market penetration potential
Multiple Sclerosis Optogenerapy
Multiple Sclerosis treatment
low-cost system
Optimal cellular engineering design
implant device
reduction of time
innovation potential
Optogenetic Protein Therapy
synthetic optogenetic gene pathway
clear exploitation plans
neuromodulation active implants
long term
GENEXPLAIN
technological push
worldwide leader
biocompatibility
discontinuation
large scale manufacturing
efficiency-losses
computer modelling
barrier requirements
immune rejection
NEOS
industrial pull
end
light
stability
specific competences
top-class consortium
BOSTON SCIENTIFIC
preclinically validated prototype
ULTRASION
Wireless powered optogenetics
Polymeric biomaterials
implantation
autonomy
research intensive SMEs
non-adherence costs
concept
s big advances
science
proof
engineered cells
minimal invasiveness
months
Micro moulding
Scientist Magazine
competitiveness
aim